Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.

Comi, Giancarlo; Alroughani, Raed; Boster, Aaron L; Bass, Ann D; Berkovich, Regina; Fernández, Óscar; Kim, Ho Jin; Limmroth, Volker; Lycke, Jan; Macdonell, Richard Al; Sharrack, Basil; Singer, Barry A; Vermersch, Patrick; Wiendl, Heinz; Ziemssen, Tjalf; Jacobs, Alan; Daizadeh, Nadia; Rodriguez, Claudio E; Traboulsee, Anthony; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.

Alemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis) studies and their exte...

ver descrição completa

Detalhes bibliográficos
Autores:	Comi, Giancarlo, Alroughani, Raed, Boster, Aaron L, Bass, Ann D, Berkovich, Regina, Fernández, Óscar, Kim, Ho Jin, Limmroth, Volker, Lycke, Jan, Macdonell, Richard Al, Sharrack, Basil, Singer, Barry A, Vermersch, Patrick, Wiendl, Heinz, Ziemssen, Tjalf, Jacobs, Alan, Daizadeh, Nadia, Rodriguez, Claudio E, Traboulsee, Anthony, CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators
Formato:	artículo
Fecha de publicación:	2019
País:	España
Recursos:	Instituto de Salud Carlos III (ISCIII)
Repositorio:	Repisalud
Idioma:	inglés
OAI Identifier:	oai:repisalud.isciii.es:20.500.12105/17936
Acesso em linha:	http://hdl.handle.net/20.500.12105/17936
Access Level:	acceso abierto
Palavra-chave:	Alemtuzumab Efficacy Multiple sclerosis Relapse Retreatment safety Humans Interferon beta-1a Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting Recurrence

id	ES_24abd80b3e262aee034ae3e00dcc1fff
oai_identifier_str	oai:repisalud.isciii.es:20.500.12105/17936
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.Comi, GiancarloAlroughani, RaedBoster, Aaron LBass, Ann DBerkovich, ReginaFernández, ÓscarKim, Ho JinLimmroth, VolkerLycke, JanMacdonell, Richard AlSharrack, BasilSinger, Barry AVermersch, PatrickWiendl, HeinzZiemssen, TjalfJacobs, AlanDaizadeh, NadiaRodriguez, Claudio ETraboulsee, AnthonyCARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ InvestigatorsAlemtuzumabEfficacyMultiple sclerosisRelapseRetreatmentsafetyAlemtuzumabHumansInterferon beta-1aMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingRecurrenceAlemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis) studies and their extensions. Subgroups were based on the number of additional alemtuzumab courses received. Exclusion criteria: other disease-modifying therapy (DMT); In the additional-courses groups, Courses 3 and 4 reduced annualized relapse rate (12 months before: 0.73 and 0.74, respectively; 12 months after: 0.07 and 0.08). For 36 months after Courses 3 and 4, 89% and 92% of patients were free of 6-month confirmed disability worsening, respectively, with 20% and 26% achieving 6-month confirmed disability improvement. Freedom from magnetic resonance imaging (MRI) disease activity increased after Courses 3 and 4 (12 months before: 43% and 53%, respectively; 12 months after: 73% and 74%). Safety was similar across groups; serious events occurred irrespective of the number of courses. Additional alemtuzumab courses significantly improved outcomes, without increased safety risks, in CARE-MS patients with continued disease activity after Course 2. How this compares to outcomes if treatment is switched to another DMT instead remains unknown.20242024-02-1020192019-11-2520192019-11-25research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articlehttp://hdl.handle.net/20.500.12105/17936reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/179362026-06-12T12:43:37Z
dc.title.none.fl_str_mv	Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
title	Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
spellingShingle	Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. Comi, Giancarlo Alemtuzumab Efficacy Multiple sclerosis Relapse Retreatment safety Alemtuzumab Humans Interferon beta-1a Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting Recurrence
title_short	Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
title_full	Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
title_fullStr	Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
title_full_unstemmed	Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
title_sort	Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
dc.creator.none.fl_str_mv	Comi, Giancarlo Alroughani, Raed Boster, Aaron L Bass, Ann D Berkovich, Regina Fernández, Óscar Kim, Ho Jin Limmroth, Volker Lycke, Jan Macdonell, Richard Al Sharrack, Basil Singer, Barry A Vermersch, Patrick Wiendl, Heinz Ziemssen, Tjalf Jacobs, Alan Daizadeh, Nadia Rodriguez, Claudio E Traboulsee, Anthony CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators
author	Comi, Giancarlo
author_facet	Comi, Giancarlo Alroughani, Raed Boster, Aaron L Bass, Ann D Berkovich, Regina Fernández, Óscar Kim, Ho Jin Limmroth, Volker Lycke, Jan Macdonell, Richard Al Sharrack, Basil Singer, Barry A Vermersch, Patrick Wiendl, Heinz Ziemssen, Tjalf Jacobs, Alan Daizadeh, Nadia Rodriguez, Claudio E Traboulsee, Anthony CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators
author_role	author
author2	Alroughani, Raed Boster, Aaron L Bass, Ann D Berkovich, Regina Fernández, Óscar Kim, Ho Jin Limmroth, Volker Lycke, Jan Macdonell, Richard Al Sharrack, Basil Singer, Barry A Vermersch, Patrick Wiendl, Heinz Ziemssen, Tjalf Jacobs, Alan Daizadeh, Nadia Rodriguez, Claudio E Traboulsee, Anthony CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators
author2_role	author author author author author author author author author author author author author author author author author author author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv	Alemtuzumab Efficacy Multiple sclerosis Relapse Retreatment safety Alemtuzumab Humans Interferon beta-1a Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting Recurrence
topic	Alemtuzumab Efficacy Multiple sclerosis Relapse Retreatment safety Alemtuzumab Humans Interferon beta-1a Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting Recurrence
description	Alemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis) studies and their extensions. Subgroups were based on the number of additional alemtuzumab courses received. Exclusion criteria: other disease-modifying therapy (DMT); In the additional-courses groups, Courses 3 and 4 reduced annualized relapse rate (12 months before: 0.73 and 0.74, respectively; 12 months after: 0.07 and 0.08). For 36 months after Courses 3 and 4, 89% and 92% of patients were free of 6-month confirmed disability worsening, respectively, with 20% and 26% achieving 6-month confirmed disability improvement. Freedom from magnetic resonance imaging (MRI) disease activity increased after Courses 3 and 4 (12 months before: 43% and 53%, respectively; 12 months after: 73% and 74%). Safety was similar across groups; serious events occurred irrespective of the number of courses. Additional alemtuzumab courses significantly improved outcomes, without increased safety risks, in CARE-MS patients with continued disease activity after Course 2. How this compares to outcomes if treatment is switched to another DMT instead remains unknown.
publishDate	2019
dc.date.none.fl_str_mv	2019 2019-11-25 2019 2019-11-25 2024 2024-02-10
dc.type.none.fl_str_mv	research article http://purl.org/coar/resource_type/c_2df8fbb1 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	http://hdl.handle.net/20.500.12105/17936
url	http://hdl.handle.net/20.500.12105/17936
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2 Attribution-NonCommercial 4.0 International http://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2 Attribution-NonCommercial 4.0 International http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv	openAccess
dc.source.none.fl_str_mv	reponame:Repisalud instname:Instituto de Salud Carlos III (ISCIII)
instname_str	Instituto de Salud Carlos III (ISCIII)
reponame_str	Repisalud
collection	Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869404713097625600
score	15,81155

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.

Registos relacionados